



**November 6, 2002**

## **Technical Brief: Duralactin**

C. Woods DVM, MS and D. Gingerich DVM, MS

Duralactin™ contains MicroLactin™, a patented milk protein concentrate from the milk of hyperimmunized cows. MicroLactin™ contains natural, biologically active factors that are believed to regulate inflammation by suppressing leukocyte migration<sup>1</sup>.

Numerous peer-reviewed research publications have demonstrated significant effects of MicroLactin™ in arthritis and other inflammatory conditions. To determine the relevance of these findings in dogs, a multi-site, double blind, placebo controlled clinical trial was jointly supported by Veterinary Products Laboratories (VPL) and Stolle Milk Biologics, Inc. (SMBI). Older, large-breed dogs with musculoskeletal disorders given MicroLactin™ showed significant improvement over placebo control dogs within the 8-week study period. An abstract of this study can be located on the VPL website ([www.vpl.com](http://www.vpl.com)) and supports prior findings in laboratory animals.

Unlike steroids and non-steroidal anti-inflammatory drugs (NSAIDs), Duralactin™ has no demonstrable cyclo-oxygenase (COX) inhibiting activity or short or long term toxic effects in any species studied thus far<sup>2</sup>. This is especially important for dogs in which long-term management of musculoskeletal disorders is indicated and the extended use of steroids or NSAIDs is contraindicated.

Duralactin is intended to be used as a nutritional aid for long term management of inflammatory conditions including musculoskeletal disorders and may diminish the need for steroid or NSAID use.

1. Ormrod, DJ and Miller TE. (1992) A low molecular weight component derived from the milk of hyperimmunized cows suppresses inflammation by inhibiting neutrophil emigration. *Agents and Actions*, **35**, 1-10.
2. Data on file with Stolle Milk Biologics, Inc. Cincinnati, OH.